Literature DB >> 23681080

Human papillomavirus is not an etiologic agent of urothelial inverted papillomas.

Riley E Alexander1, Darrell D Davidson, Antonio Lopez-Beltran, Rodolfo Montironi, Gregory T MacLennan, Eva Compérat, Muhammad T Idrees, Robert E Emerson, Liang Cheng.   

Abstract

Inverted papilloma of the urinary bladder is rare, accounting for <1% of all bladder neoplasms. Although there is general consensus that inverted papilloma is benign in nature, little is known about its pathogenesis. Some have suggested that human papillomavirus (HPV) plays an etiologic role in the development of this neoplasm. These claims have not been adequately substantiated, and there is controversy as to the role of HPV in other urinary bladder neoplasms as well. To further investigate a possible etiologic role of HPV in urothelial neoplasia, we evaluated 27 inverted papillomas of the urinary bladder for the presence of HPV. Both immunohistochemical and in situ hybridization (ISH) studies for HPV and immunohistochemical analysis for p16, a surrogate marker for HPV infection, were used to assess HPV infection status. In the urinary bladder inverted papillomas of these 27 patients (age range, 35 to 78 y; M:F ratio, 11:1), no HPV was detected by HPV immunohistochemistry or by ISH. Immunoreactivity to p16 was detected in 11/27 (41%) of the cases. Expression of p16 is seen inconsistently within these neoplasms and does not correlate with the presence of HPV antigens or genes by immunohistochemistry or ISH, respectively. Therefore, p16 is not a reliable surrogate marker for HPV infection in urothelial inverted papilloma. Our findings indicate the absence of HPV in urothelial inverted papillomas. HPV testing should not be used as a diagnostic adjunct for inverted papilloma cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681080     DOI: 10.1097/PAS.0b013e3182863fc1

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

Review 1.  Inverted urothelial papilloma: A review of diagnostic pitfalls and clinical management.

Authors:  Mary K Sweeney; Soroush Rais-Bahrami; Jennifer Gordetsky
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

3.  The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.

Authors:  Julie Steinestel; Andreas Al Ghazal; Annette Arndt; Thomas J Schnoeller; Andres J Schrader; Peter Moeller; Konrad Steinestel
Journal:  BMC Cancer       Date:  2015-04-03       Impact factor: 4.430

4.  Osteotomy Techniques for Spinal Deformity.

Authors:  Wen-Hao Hu; Yan Wang
Journal:  Chin Med J (Engl)       Date:  2016-11-05       Impact factor: 2.628

Review 5.  Prevalence of Human Papilloma Virus Infection in Bladder Cancer: A Systematic Review.

Authors:  Narcisa Muresu; Biagio Di Lorenzo; Laura Saderi; Illari Sechi; Arcadia Del Rio; Andrea Piana; Giovanni Sotgiu
Journal:  Diagnostics (Basel)       Date:  2022-07-20

6.  HRAS mutations are frequent in inverted urothelial neoplasms.

Authors:  Andrew S McDaniel; Yali Zhai; Kathleen R Cho; Saravana M Dhanasekaran; Jeffrey S Montgomery; Ganesh Palapattu; Javed Siddiqui; Todd Morgan; Ajjai Alva; Alon Weizer; Cheryl T Lee; Arul M Chinnaiyan; Michael J Quist; Catherine S Grasso; Scott A Tomlins; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-06-18       Impact factor: 3.466

7.  Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma.

Authors:  Katsuya Matsuda; Tatsuhiko Kawasaki; Yuko Akazawa; Yuhmi Hasegawa; Hisayoshi Kondo; Keiji Suzuki; Masachika Iseki; Masahiro Nakashima
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.